Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?

GRAL shares have fallen from a record $116.06 to under $70 after the company's Galleri blood cancer test failed to gain traction in an NHS England trial. The setback hits the core premise behind Grail's early-detection technology, which aims to screen for multiple cancer types through a single blood draw.

Despite the NHS disappointment, Grail continues generating revenue through direct-to-consumer channels. The company posted $147 million in sales for 2025 and analysts project revenue climbing to $281 million by 2028. That growth trajectory hinges on broader adoption outside the U.K. public health system and potential regulatory wins in the U.S. market.

The Motley Fool reports analysts are recommending a hold stance on GRAL at current levels. The bull case rests on FDA approval for Galleri, which would open commercial pathways beyond cash-pay consumers and provide reimbursement optionality that could accelerate uptake. Without that regulatory clearance, the stock remains tied to a slower direct-to-sale model and limited institutional adoption.